Patents by Inventor David C. Yeomans

David C. Yeomans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210002331
    Abstract: Disclosed are 13N-oxytocin molecules, methods of manufacture of 13N-oxytocin molecules and methods of use of 13N-oxytocin molecules in the determination of the distribution and kinetics of 13N-oxytocin molecules after craniofacial or other application methods.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Steen Jakobsen, Michael Winterdahl, Erik Holm Nielsen, David C. Yeomans, Dean Carson
  • Patent number: 10513525
    Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: December 24, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Justin Du Bois, John Mulcahy, Brian Andresen, David C. Yeomans, Sandip Biswal
  • Publication number: 20190374644
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 12, 2019
    Inventors: Julien MAMET, Scott HARRIS, George MILJANICH, Rick ORR, William K. SCHMIDT, Tony YAKSH, David C. YEOMANS
  • Patent number: 10434178
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 8, 2019
    Assignee: Adynxx Sub, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
  • Publication number: 20190175686
    Abstract: Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in a patient suffering from an autism spectrum disorder.
    Type: Application
    Filed: April 12, 2017
    Publication date: June 13, 2019
    Applicant: Trigemina, Inc.
    Inventors: Dean CARSON, David C. YEOMANS
  • Publication number: 20180015165
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 18, 2018
    Applicant: Adynxx, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
  • Publication number: 20170368095
    Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 28, 2017
    Applicant: Trigemina, Inc.
    Inventors: David C. YEOMANS, Dean CARSON, Ramachandran THIRUCOTE
  • Patent number: 9700624
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: July 11, 2017
    Assignee: Adynxx, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yaksh, David C Yeomans
  • Patent number: 9629894
    Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: April 25, 2017
    Assignee: TRIGEMINA, INC.
    Inventors: David C. Yeomans, Dean Carson, Ramachandran Thirucote
  • Publication number: 20160193282
    Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
    Type: Application
    Filed: January 7, 2016
    Publication date: July 7, 2016
    Inventors: David C. YEOMANS, Dean CARSON, Ramachandran THIRUCOTE
  • Publication number: 20160115173
    Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.
    Type: Application
    Filed: October 26, 2015
    Publication date: April 28, 2016
    Inventors: Justin DU BOIS, John MULCAHY, Brian ANDRESEN, David C. YEOMANS, Sandip BISWAL
  • Patent number: 9238053
    Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 19, 2016
    Assignee: Nocicepta LLC
    Inventors: Lawrence R. Toll, David C. Yeomans, Martin S. Angst, Daniel I. Jacobs
  • Patent number: 9174999
    Abstract: Saxitoxin analog compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogs, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analog binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 3, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Justin Du Bois, John Mulcahy, Brian Andresen, David C. Yeomans, Sandip Biswal
  • Publication number: 20150111956
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: May 9, 2013
    Publication date: April 23, 2015
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yakash, David C Yeomans
  • Patent number: 8551949
    Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: October 8, 2013
    Assignee: Nocicepta LLC
    Inventors: Lawrence R. Toll, David C. Yeomans, Martin S. Angst, Daniel I. Jacobs
  • Patent number: 8501691
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 6, 2013
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research & Education
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20120322736
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Application
    Filed: May 24, 2012
    Publication date: December 20, 2012
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Patent number: 8258096
    Abstract: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: September 4, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, William H. Frey, II, Daniel I. Jacobs, Martin S. Angst
  • Patent number: 8252745
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: August 28, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Patent number: 8202838
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: June 19, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs